Full Press Release Details
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera
Vamorolone is a Promising
Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy
Synergistic Novel Asset Leverages Catalyst s Expertise and Bolsters Catalyst s Rare Neuroscience Portfolio
Granted FDA Fast Track, Orphan Drug Designation, and a PDUFA Action Date of October 26, 2023
Catalyst Expects to Launch Vamorolone in the U.S. Early in Q1 2024, Subject to Regulatory Approval
CORAL GABLES, Fla., July 19, 2023 Catalyst Pharmaceuticals, Inc. ( Catalyst or Company ) (Nasdaq:
CPRX), today announced the completion of its acquisition from Santhera Pharmaceuticals Holdings ( Santhera ) of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular
Dystrophy. The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, Catalyst will hold
North American rights for any future approved indications of vamorolone.
Vamorolone is a promising best-in-class dissociative anti-inflammatory steroid treatment for Duchenne Muscular Dystrophy ( DMD ). In clinical studies, vamorolone demonstrated efficacy with a significant reduction of
steroid-associated side effects and benefits for bone health, growth, and behavior, offering the potential to address an important unmet medical need in DMD patients. Vamorolone has received FDA Orphan Drug and Fast Track designations and has been
granted a PDUFA action date of October 26, 2023.
With the addition of vamorolone, we have accomplished another important milestone in the
execution of our portfolio expansion strategy, stated Patrick J. McEnany, Chairman and CEO of Catalyst. The license for vamorolone reflects our strategic focus on opportunities where we can not only apply novel technology to address
critical unmet patient needs, but where we can leverage Catalyst s existing integrated capabilities and infrastructure to commercialize the drug efficiently. We believe that vamorolone, if approved, has the potential to deliver significant near
and long-term value and to be a very meaningful advancement to the current standard of care paradigm for DMD patients.
Mr. McEnany continued,
Vamorolone fortifies our neuromuscular portfolio with an innovative therapy that, in clinical studies, demonstrated an enhanced safety and tolerability profile as compared to prednisone. We plan to include vamorolone for DMD patients in our
Catalyst Pathways specialty pharmacy program to help ensure that all patients have access to the full patient benefits of the program. Our planned strategy to facilitate
access to vamorolone underscores our steadfast commitment to improving the lives of patients suffering from rare neurological conditions.
Duchenne Muscular Dystrophy, or DMD, the most common form of muscular dystrophy, is a rare, fatal
neuromuscular disorder characterized by progressive muscular dysfunction, leading to loss of ambulation, respiratory failure, and death. Corticosteroids are the current standard of care for treating DMD; however, this treatment is associated with
significant side effect burdens. The U.S. prevalence for DMD is estimated to be between 11,000 and 13,000 patients. Of patients currently being treated for DMD, approximately 75% receive concomitant steroid treatment.
As previously disclosed, Catalyst
has made an all-cash purchase payment of $75 million to acquire the license. Simultaneously, Catalyst has made a strategic equity investment into Santhera by acquiring 1,414,688 of Santhera s
post reverse-split ordinary shares (representing approximately 11.26% of Santhera s outstanding ordinary shares following the transaction) at an investment price of CHF 9.477 (corresponding to a mutually agreed volume-weighted average
price prior to signing), with the approximately $15 million USD in equity investment proceeds to be used by Santhera for Phase IV studies in DMD and further development of additional indications for vamorolone. Catalyst will also be
obligated under certain circumstances to make milestone payments and to pay royalties to Santhera.
Vamorolone Commercial Operational Plan
Further details on the vamorolone commercial operational plan will be discussed during the Company s second-quarter 2023 financial results conference
call, which is expected to be held in the second week of August. Catalyst also expects to discuss on a preliminary basis the anticipated accounting treatment for the transaction on the conference call.
Vamorolone is an investigational drug
candidate with a mode of action based on binding to the same receptor as glucocorticoids but modifying its downstream activity and as such, is considered a dissociative anti-inflammatory steroid drug [2-5].
This mechanism has shown the potential to dissociate efficacy from steroid safety concerns, and therefore vamorolone could emerge as an alternative to existing corticosteroids, the current standard of care in children, adolescent, and
adult patients with DMD. In the pivotal VISION-DMD study, vamorolone met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and
tolerability profile [1]. The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, vomiting, and vitamin D deficiency. Adverse events were generally of mild
to moderate severity.
Vamorolone has been granted Orphan Drug status for DMD in the U.S. and Europe and has
received Fast Track and Rare Pediatric Disease designations by the U.S. FDA and Promising Innovative Medicine (PIM) status from the UK MHRA for DMD. Vamorolone is an investigational medicine and is currently not approved for use
by any health authority.
Vamorolone will be eligible for 7 years of orphan drug exclusivity upon approval and also has issued and pending patents that
could provide protection to 2040.
[1] Guglieri M et al (2022). JAMA Neurol.
2022;79(10):1005-1014.doi:10.1001/jamaneurol.2022.2480. Link.
[2] Mah JK et al (2022). JAMA Netw Open. 2022;5(1):e2144178.
doi:10.1001/jamanetworkopen.2021.44178. Link.
[3] Guglieri M et al (2022) JAMA. doi:10.1001/jama.2022.4315
[4] Heier CR et al (2019). Life Science Alliance DOI: 10.26508
[5] Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293
About Duchenne Muscular Dystrophy
Dystrophy ( DMD ) is a rare inherited X-chromosome-linked disease, which almost exclusively affects males. DMD is characterized by muscle inflammation and damage which are present at birth or shortly
thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of self-feeding, the start of assisted
ventilation, and the development of cardiomyopathy. DMD reduces life expectancy to before the fourth decade due to respiratory and/or cardiac failure. Corticosteroids are the current standard of care for the treatment of DMD.
About Catalyst Pharmaceuticals
With exceptional patient
focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases. Catalyst s
U.S. commercial product portfolio consists of FIRDAPSE (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ( LEMS ) for adults and
children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights of FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four
and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures, and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.
Further, Canada s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
For more information, visit the Company s website at www.catalystpharma.com. For Full
Prescribing and Safety Information for FIRDAPSE , please visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA , please visit www.fycompa.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause
Catalyst s actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether the NDA for vamorolone will be approved by the PDUFA date, or at all, (ii) whether, if the NDA for
vamorolone is approved by the FDA, the product can be successfully commercialized by Catalyst in the licensed territory, (iii) whether if vamorolone is commercialized by Catalyst, the results of operations will prove to be accretive to
Catalyst, (iv) whether Catalyst and Santhera will successfully develop additional indications for vamorolone and obtain the approvals required to commercialize the product in the licensed territory for those additional indications,
(v) whether, if vamorolone is commercialized by Catalyst, the drug will be successfully integrated into Catalyst s business activities, and (vi) those factors described in Catalyst s Annual Report on Form 10-K for the 2022 fiscal year, Catalyst s Quarterly Report on Form 10-Q for the first quarter of 2023, and Catalyst s other filings with the SEC, could
adversely affect Catalyst. Copies of Catalyst s filings with the SEC are available from the SEC, may be found on Catalyst s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any
obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.